Updated: January 29, 2026
Alternatives to Mycophenolate Mofetil If You Can't Fill Your Prescription
Author
Peter Daggett

Summarize with AI
- First Option: Switch to a Different Mycophenolate Formulation
- Alternative 1: Azathioprine (Imuran) — The Most Common Substitute
- Alternative 2: Tacrolimus (Prograf) — For Transplant Patients
- Alternative 3: Cyclosporine (Neoral, Sandimmune) — Older Transplant Option
- Alternative 4: Sirolimus (Rapamune) or Everolimus (Zortress)
- Alternatives Specifically for Autoimmune Conditions
- Questions to Ask Your Provider Before Switching
- The Bottom Line
When mycophenolate mofetil is out of stock, what are your options? This guide covers the main alternatives for transplant recipients and autoimmune patients — and when to use them.
Mycophenolate mofetil (CellCept) shortages have left many transplant and autoimmune patients searching for options. This is one of the most anxiety-inducing situations a patient on long-term immunosuppression can face — because skipping doses is not safe, but neither is switching medications without guidance.
This article reviews the main alternatives to mycophenolate mofetil, organized by indication. Every switch discussed here requires a conversation with your prescriber — this information is meant to help you have an informed discussion, not to guide self-substitution.
First Option: Switch to a Different Mycophenolate Formulation
Before considering a different drug entirely, explore whether a different form of mycophenolate is available:
- Brand-name CellCept (Genentech): If generic mycophenolate mofetil is unavailable, brand-name CellCept may still be in stock. It contains the exact same active ingredient. With the Genentech savings card, eligible patients may pay as little as $15/month. Ask your prescriber to specify 'brand only' on the prescription.
- Switch strength/form: If 500 mg tablets are unavailable, 250 mg capsules may be in stock (just take two capsules where you'd take one tablet). If swallowing is a problem, Myhibbin oral suspension (200 mg/mL) was FDA-approved in 2024.
- Mycophenolate sodium (Myfortic): Myfortic is the enteric-coated, delayed-release formulation of mycophenolate sodium. It delivers the same active drug (mycophenolic acid) as mycophenolate mofetil, but is NOT milligram-equivalent — 720 mg/day of mycophenolate sodium is roughly equivalent to 2 g/day of mycophenolate mofetil. This requires a new prescription with dose adjustment.
Alternative 1: Azathioprine (Imuran) — The Most Common Substitute
Azathioprine is the most frequently used alternative to mycophenolate mofetil across multiple indications, including organ transplant rejection prevention, lupus, vasculitis, and autoimmune hepatitis.
- How it works: Like MMF, azathioprine is a purine antimetabolite that suppresses T and B cell proliferation. Its active metabolite is 6-mercaptopurine (6-MP).
- Important before starting: Requires testing for TPMT (thiopurine methyltransferase) enzyme activity. Patients with low TPMT activity are at high risk of severe bone marrow suppression. Your prescriber must check this before or shortly after starting azathioprine.
- Clinical evidence: In lupus nephritis maintenance therapy, mycophenolate mofetil has been shown superior to azathioprine in some trials (treatment failure rate 16% vs. 32%), but azathioprine remains a guideline-recommended alternative. In transplant, both drugs are used, with MMF generally preferred in contemporary practice.
- Cost: Generic azathioprine is typically less expensive than generic mycophenolate mofetil and widely available. Note: Azathioprine itself has faced injectable shortage issues, though oral tablets have remained generally accessible.
Alternative 2: Tacrolimus (Prograf) — For Transplant Patients
Tacrolimus is a calcineurin inhibitor widely used in transplant immunosuppression. In most transplant regimens, tacrolimus and mycophenolate mofetil are used together — so tacrolimus is not a direct replacement, but the transplant team may modify the tacrolimus dose if MMF is unavailable for a period.
- How it works: Tacrolimus inhibits calcineurin, blocking the production of interleukin-2 (IL-2) and suppressing T cell activation. Its mechanism is different from mycophenolate's.
- Key risks: Nephrotoxicity (kidney damage), neurotoxicity, hypertension, diabetes, and high sensitivity to dose changes. Requires careful drug level monitoring.
Any adjustment to tacrolimus dosing in the context of a transplant must be managed entirely by your transplant team. Do not adjust tacrolimus on your own.
Alternative 3: Cyclosporine (Neoral, Sandimmune) — Older Transplant Option
Cyclosporine is an older calcineurin inhibitor still used in some transplant regimens. In autoimmune diseases like lupus nephritis, it is also used as a steroid-sparing agent. Cyclosporine has a well-established profile but more drug interactions and toxicities than newer agents. It is not typically used as an emergency substitute for mycophenolate — rather, it might be part of a reformulated regimen designed by a transplant team.
Alternative 4: Sirolimus (Rapamune) or Everolimus (Zortress)
Sirolimus and everolimus are mTOR inhibitors used in kidney transplant — primarily as an alternative when calcineurin inhibitors are causing nephrotoxicity. They are not commonly used as emergency substitutes for mycophenolate mofetil, but your transplant team may consider them as part of a regimen restructure. Both are expensive and require careful monitoring.
Alternatives Specifically for Autoimmune Conditions
For patients taking mycophenolate mofetil for autoimmune disease rather than transplant, the alternative landscape is broader:
- Lupus/lupus nephritis: Azathioprine is the main alternative for maintenance therapy. For induction or severe flares, cyclophosphamide (IV or oral) may be used under close supervision.
- Vasculitis: Azathioprine is the primary maintenance alternative. Methotrexate may also be considered in non-renal disease.
- Myasthenia gravis: Azathioprine and cyclosporine are the main alternatives. Rituximab is used in refractory cases.
- Pemphigus vulgaris: Rituximab is now considered first-line by many experts. Azathioprine and cyclophosphamide are alternatives.
- IgA nephropathy: Supportive care (blood pressure control, RAS blockade) is central. Newer targeted agents (sparsentan, budesonide) are emerging options.
Questions to Ask Your Provider Before Switching
When you call your transplant team or rheumatologist about a shortage, come prepared with these questions:
- Is mycophenolate sodium (Myfortic) an acceptable substitute for me, and what would the equivalent dose be?
- If I need to switch to azathioprine, do I need TPMT testing first?
- How long is it safe to bridge without any mycophenolate if we can't source it immediately?
- Do you have any samples or can the clinic dispense a few days' supply while I locate stock?
The Bottom Line
The safest first step when you can't find mycophenolate mofetil is to contact your prescriber and simultaneously search for stock at other pharmacies. medfinder can call pharmacies near you to check which ones have your medication in stock, helping you find it faster. Many patients locate their medication at a pharmacy they wouldn't have thought to call — without needing to switch drugs at all.
For a full practical search guide, see: How to Find Mycophenolate Mofetil in Stock Near You. For shortage background, see: Why Is Mycophenolate Mofetil So Hard to Find?.
Frequently Asked Questions
Mycophenolate sodium (Myfortic) delivers the same active drug — mycophenolic acid — and is the closest therapeutic equivalent. Note that 720 mg/day of mycophenolate sodium is approximately equivalent to 2 g/day of mycophenolate mofetil. This is not a milligram-for-milligram substitution; a new prescription with adjusted dosing is required.
No. You should never switch immunosuppressant medications without your prescriber's guidance. Azathioprine requires TPMT enzyme testing before use, and the dosing and monitoring approach differs significantly from mycophenolate. An unsupervised switch could result in dangerous over- or under-immunosuppression.
Mycophenolate sodium (Myfortic) and mycophenolate mofetil (CellCept) both deliver the same active compound — mycophenolic acid — but they are different salts with different pharmacokinetics. They are not interchangeable milligram for milligram. A prescriber must calculate the appropriate Myfortic dose when switching from CellCept.
Most transplant centers first try to locate an alternative formulation of mycophenolate (brand-name CellCept, a different strength, or Myfortic). If the drug truly cannot be sourced, some centers consider a temporary bridge with a modified tacrolimus regimen or a switch to azathioprine with careful monitoring. Each decision is patient-specific.
Medfinder Editorial Standards
Medfinder's mission is to ensure every patient gets access to the medications they need. We are committed to providing trustworthy, evidence-based information to help you make informed health decisions.
Read our editorial standardsPatients searching for Mycophenolate Mofetil also looked for:
More about Mycophenolate Mofetil
32,827 have already found their meds with Medfinder.
Start your search today.





